Skip to main content
SpringerLink
Log in

Parathyroid hormone analogues in the therapy of osteoporosis

  • Perspective
  • Published:
Wiener klinische Wochenschrift Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Jaglal SB, Weller I, Mamdani M, Hawker G, Kreder H, Jaakkimainen L, Adachi JD (2005) Population trends in BMD testing, treatment, and hip and wrist fracture rates: are the hip fracture projections wrong? J Bone Miner Res 20(6): 898–905

    Article  PubMed  Google Scholar 

  • Blahos J (2007) Treatment and prevention of osteoporosis. Wien Med Wochenschr 157(23–24): 589–592

    Article  PubMed  Google Scholar 

  • Riggs BL, Parfitt MA (2005) Perspective Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodelling. J Bone Miner Res 20(2): 177–184

    Article  PubMed  CAS  Google Scholar 

  • Sato M, Zeng GQ, Turner CH (1997) Biosynthetic human parathyroid hormone (1–34) effects on bone quality in aged ovariectomized rats. Endocrinology 138(10): 4330–4337

    Article  PubMed  CAS  Google Scholar 

  • Jerome CP, Burr DB, Van Bibber T, Hock JM, Brommage R (2001) Treatment with human parathyroid hormone (1–34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 28(2): 150–159

    Article  PubMed  CAS  Google Scholar 

  • Sato M, Westmore M, Clendenon J, Smith S, Hannum B, Zeng GQ, Brommage R, Turner CH (2000) Three-dimensional modeling of the effects of parathyroid hormone on bone distribution in lumbar vertebrae of ovariectomized cynomolgus macaques. Osteoporos Int 11(10): 871–880

    Article  PubMed  CAS  Google Scholar 

  • www.emea.europa.eu/humandocs/Humans/EPAR/forsteo/forsteo.htm

  • www.emea.europa.eu/humandocs/Humans/EPAR/preotact/preotact.htm

  • Canalis E, Giustina A, Bilezikian JP (2007) Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357(9): 905–916

    Article  PubMed  CAS  Google Scholar 

  • Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344(19): 1434–1441

    Article  PubMed  CAS  Google Scholar 

  • CPMP Guideline on the evaluation of new medicinal products in the treatment of primary osteoporosis. EMEA www.emea.europa.eu/pdfs/human/ewp/55295enfin.pdf

  • Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB (2007) Treatment of Osteoporosis with Parathyroid Hormone Study Group. Effect of recombinant human parathyroid hormone (1–84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 146(5): 326–339

    PubMed  Google Scholar 

  • Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ (2005) PaTH Study Investigators. One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med 353(6): 555–565

    Article  PubMed  CAS  Google Scholar 

  • D'Amour P (2006) Circulating PTH molecular forms: What we know and what we don't. Kidney International 70: S29–S33

    Article  Google Scholar 

  • Ettinger B, San Martin J, Crans G, Pavo I (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19(5): 745–751

    Article  PubMed  CAS  Google Scholar 

  • Boonen S, Marin F, Obermayer-Pietsch B, Simões ME, Barker C, Glass EV, Hadji P, Lyritis G, Oertel H, Nickelsen T, McCloskey EV, for the EUROFORS Investigators (2008) Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 93(3): 852–860

    Article  PubMed  CAS  Google Scholar 

  • Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ (2003) PaTH study investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausalosteoporosis. N Engl J Med 349(13): 1207–1215

    Article  PubMed  CAS  Google Scholar 

  • Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349(13): 1216–1226

    Article  PubMed  CAS  Google Scholar 

  • Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R (2005) Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 353(6): 566–575

    Article  PubMed  CAS  Google Scholar 

  • Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen C, Reginster JY, Stepan JJ, Myers SL, Mitlak BH (2004) Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 164(18): 2024–2030

    Article  PubMed  Google Scholar 

  • Jódar-Gimeno E (2007) Full length parathyroid hormone (1–84) in the treatment of osteoporosis in postmenopausal women. Clin Interv Aging 2(1): 163–174

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Universität Wien/AKH, Universitätsklinik für Klinische Pharmakologie, AKH-Wien, Vienna, Austria

    Markus Müller

Authors
  1. Markus Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Pietschmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Markus Müller.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Müller, M., Pietschmann, P. Parathyroid hormone analogues in the therapy of osteoporosis. Wien Klin Wochenschr 120, 321–324 (2008). https://doi.org/10.1007/s00508-008-0999-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00508-008-0999-0

Keywords

Search

Navigation